Accès gratuit
Numéro
Med Sci (Paris)
Volume 19, Numéro 5, Mai 2003
Page(s) 613 - 619
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2003195613
Publié en ligne 15 mai 2003
  1. Forno LS. The Lewy body in Parkinson’s disease. Adv Neurol 1987; 45: 35–43.
  2. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–80.
  3. Lansbury PT, Brice A. Genetics of Parkinson’s disease and biochemical studies of implicated gene products. Curr Opin Genet Dev 2002; 12: 299–306.
  4. Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and alphasynuclein. Nat Rev Neurosci 2002; 3: 932–42.
  5. Kahle PJ, Haass C, Kretzschmar HA, Neumann M/S n° 5, vol. 19, mai 2003 M. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson’s and related diseases. J Neurochem 2002; 82: 449–57.
  6. Spillantini MG, Schmidt ML, Lee VM, et al. Alphasynuclein in Lewy bodies. Nature 1997; 388: 839–40.
  7. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002; 22: 2780–91.
  8. Klein RL, King MA, Hamby ME, Meyer EM. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 2002; 13: 605–12.
  9. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. Alphasynucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci USA 2002; 99: 10813–8.
  10. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of alphasynuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002; 8: 600–6.
  11. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopaminealpha- synuclein adduct. Science 2001; 294: 1346–9.
  12. Conway KA, Lee SJ, Rochet JC, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alphasynuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97: 571–6.
  13. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002; 418: 291.
  14. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitinprotein ligase. Nat Genet 2000; 25: 302–5.
  15. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 2001; 293: 263–9.
  16. Giasson BI, Lee VM. Parkin and the molecular pathways of Parkinson’s disease. Neuron 2001; 31: 885–8.
  17. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 2002; 111: 209–18.
  18. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256–9.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.